Brii Biosciences Limited (HKG:2137)

Revenue by Product

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2023	Dec 31, 2022
Therapies for Infectious Diseases and Central Nervous System Diseases	681.78K
Therapies for Infectious Diseases and Central Nervous System Diseases Growth	-98.86%

Revenue by Geography

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2023	Dec 31, 2022
China	681.78K
China Growth	-98.86%